When Srikanth Singamaneni and Guy Genin, both professors of mechanical engineering and materials science at the McKelvey School of Engineering at Washington University in St. Louis, established a new collaboration with researchers from the School of Medicine in late 2019, they didn’t know the landscape of infectious disease research was about to shift dramatically. In a conference room overlooking Forest Park on a beautiful fall day, the team had one goal in mind: tackle the biggest infectious disease problem facing the world right then.
“Greg Storch told us that one of the most important challenges facing the field of infectious disease is finding a way to figure out quickly if a patient has a bacterial infection and should get antibiotics or has a viral infection, for which antibiotics will not be effective.”
Storch, MD, the Ruth L. Siteman Professor of Pediatrics at the School of Medicine, was interested in diseases that affect most people regularly—colds, strep throat or the flu—but that weren’t getting as much research attention as rarer diseases. “Even with great advances that have been made in infectious disease diagnostics, there is still a niche for tests that are simple, rapid and sensitive,” Storch said. “It would be especially powerful if they could provide quantitative information. Tests with these characteristics could be employed in sophisticated laboratories or in the field.”
Drawing on his years of experience in developing nanomaterials for applications in biology and medicine, Singamaneni, the Lilyan & E. Lisle Hughes Professor, sought to overcome these limitations in point-of-care diagnostic tests. Singamaneni and his lab developed ultrabright fluorescent nanolabels called plasmonic-fluors, which could be quickly integrated into a common testing platform, the lateral flow assay (LFA).
Plasmon-enhanced LFAs (p-LFAs) improve inexpensive, readily available rapid tests to levels of sensitivity required by physicians for confidence in test results without the need for lab-based confirmation.
According to findings published Feb. 2 in Nature Biomedical Engineering, the team’s p-LFAs are 1,000 times more sensitive than conventional LFAs, which show results via a visual color and fluorescence signal on the strip. When analyzed using a fluorescence scanner, p-LFAs are also substantially faster than gold-standard lab tests, returning results in only 20 minutes instead of several hours, with comparable or improved sensitivity. The p-LFAs can detect and quantify concentrations of proteins, enabling them to detect bacterial and viral infections as well as markers of inflammation that point to other diseases.
“Our p-LFAs can pick up even very small concentrations of antibodies and antigens, typical markers of infection, and give clinicians clear, quick results without the need for specialized equipment. For quantitative testing beyond the initial screening, the same LFA strip can be scanned with a fluorescence reader, enabling rapid and ultrasensitive colorimetric and fluorometric detection of disease markers with only one test.”
“It’s like turning up the volume on standard color-changing test strips. Instead of getting a faint line indicating only a positive or negative result, the new p-LFAs give clearer results with fewer particles, enabling one to move from simply ‘yes or no?’ to exactly ‘how much?’ with the aid of an inexpensive, portable scanner,” said Jeremiah Morrissey, a research professor in anesthesiology in the Division of Clinical and Translational Research at the School of Medicine. Morrissey is a co-author of the new study and a long-term collaborator with the Singamaneni lab.
This improved testing capability has obvious benefits for a population now all too familiar with the need for quick and reliable test results and the risk of false negatives.
“When we took on this problem in 2019, we thought our biggest challenge would be getting an adequate number of samples from sick people,” Genin recalled. “Where on Earth could we find a massive set of samples from patients whose symptoms were carefully documented and whose diagnosis was verified by slow and expensive PCR tests?” In a matter of months, COVID-19 would erase that obstacle while introducing a whole host of new challenges and opportunities.
“The pandemic was a big shift for us, like it was for everyone,” said first author Rohit Gupta, who worked on the p-LFA study as a graduate student in Singamaneni’s lab and is now a senior scientist at Pfizer. “We had to move away from our original focus on distinguishing viruses from bacteria, but it turned out to be an opportunity to do practical science with real stakes. We were working with epidemiologists to get samples for testing, with diagnosticians to compare our test to what was available, and with clinicians to gain insights into the real needs for patient care.”
Input from the entire collaboration helped Gupta and Singamaneni refine the design of the p-LFAs, which ultimately achieved 95% clinical sensitivity and 100% specificity for SARS-CoV-2 antibodies and antigens. Genin described the results as stunning.
“We didn’t know it was going to work so well,” he said. “We knew it would be good, but we didn’t know this $1 test with a $300 readout device would be so much better—10 times better—than state of the art that we all used during the COVID pandemic.”
Now that they’ve proven p-LFAs can outperform standard lab tests in sensitivity, speed, convenience and cost for one disease, the team is looking to develop new applications for the technology, including returning to their original goal of identifying bacterial versus viral infections and getting their diagnostic tool into the hands of physicians around the world.
The p-LFA technology has been licensed to Auragent Bioscience LLC by Washington University’s Office of Technology Management. Singamaneni and Morrissey are among the co-founders of Auragent, a WashU startup.
“We expect to have p-LFAs commercially available in the next one to two years,” Singamaneni said. “Right now, we’re working on improving our portable scanner technology, which adds a more sensitive, fluorescent reading capability to the test strips in addition to the color change that can be seen with the naked eye. We think we can get that cost down to a point where it’s accessible to rural clinics in the U.S. and abroad, which was one of our original goals.”
“We’re also excited about the potential to detect many more diseases than COVID, possibly using a skin patch that can take a painless sample,” Singamaneni added. “This technology has the potential to detect any number of diseases, ranging from STIs to respiratory infections and more, as well as cytokines indicative of inflammation seen in conditions such as rheumatoid arthritis and sepsis.”
News
Antibody engineering drives innovation in drug development
Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable and communicable diseases. Over the past few years, the market for mAbs has grown exponentially with an expected compound [...]
Breakthrough Study Reveals How Bladder Cancer Starts and Spreads
Researchers found that DNA mutations from antiviral enzymes and chemotherapy fuel early bladder cancer, while abnormal circular DNA in tumor cells drives resistance to therapy. These discoveries open new therapeutic avenues. A groundbreaking study led by [...]
AI and Quantum Mechanics Accelerate Drug Discovery
A recent article published in the Journal of Chemical Information and Modeling researchers at Southern Methodist University (SMU) have developed SmartCADD, an open-source virtual tool designed to speed [...]
Targeting ‘undruggable’ diseases: Researchers reveal new levels of detail in targeted protein degradation
Researchers at the University of Dundee have revealed in the greatest detail yet the workings of molecules called protein degraders which can be deployed to combat what have previously been regarded as "undruggable" diseases, [...]
Revolutionizing Virology: AI Discovers Over 160,000 New RNA Viruses
Largest discovery of new virus species sheds light on the hidden virosphere. Artificial intelligence (AI) has been used to reveal details of a diverse and fundamental branch of life living right under our feet and in every [...]
Cardiac Crisis: COVID-19 Doubles Risk of Heart Attacks, Strokes, and Death
Research indicates that COVID-19 survivors face doubled risks of severe cardiac events for years after recovery, especially if hospitalized. People with A, B, or AB blood types are particularly vulnerable, highlighting the need for personalized approaches [...]
AI steps into science limelight with Nobel wins
For long periods of its history, artificial intelligence has lurked in the hinterland of science, often unloved and unfunded—but two Nobel prizes in one week suggest its time in the sunshine has finally arrived. [...]
MIT Scientists Shed New Light on the Critical Brain Connections That Define Consciousness
A new study provides further evidence that consciousness depends on communication between the brain’s sensory and cognitive regions in the cortex. Our brains are constantly making predictions about our surroundings, enabling us to focus [...]
Common Chemicals Found in Shampoo and Plastic Could Be Quietly Disrupting Your Heart’s Rhythm
UC study of Fernald data links environmental phenols to heart toxicities Environmental phenols are present in numerous everyday consumer products, serving as preservatives in packaged foods, parabens in shampoos, and bisphenol A (BPA) in [...]
Revolutionary Brain Tech Offers New Hope for Stroke and Injury Recovery
University of Pittsburgh researchers report that deep brain stimulation (DBS) can effectively enhance motor functions in individuals with arm and hand paralysis due to brain injuries, with promising results from early human and monkey [...]
NIH Scientists Discover Gene Responsible for Rare Eye Disease
Findings supported by the NIH pave the way for the development of genetic testing, clinical trials, and therapies. Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a gene linked to certain [...]
Alzheimer’s Breakthrough: Synthetic THC Pill Proves Effective in Clinical Trial
Patients tolerated synthetic THC (dronabinol) well, without the adverse effects commonly associated with existing Alzheimer’s agitation medications. A study conducted by researchers from Johns Hopkins University School of Medicine and Tufts University School of Medicine found that a pill form [...]
The Future of Rare Disease Treatment with Precision Medicine
Understanding rare diseases Rare diseases affect less than 5 people out of 10,000. However, this still amounts to about 7% of the world’s population, with over 10,000 such conditions. Almost all are genetic in [...]
Doctors issue warning for upcoming ‘tripledemic
The term ‘tripledemic’ has hit headlines this week as the NHS begins its Covid and fluvaccine roll-out for vulnerable adults. As the cold weather sets in, many of us have experienced a decline in health, and this may [...]
The FDA approved a gel that can stop bleeding from wounds in seconds
Aug 15 (Reuters) - The U.S. Food and Drug Administration has cleared Cresilon's gel to quickly control bleeding, the privately held company said on Thursday, potentially giving emergency medical technicians and combat medics a [...]
High levels of microplastics found in prostate tumors, possibly linked to take-out food
The presence of microplastics in prostate tumors points to potential health risks, and researchers are calling for urgent studies to explore how take-out food may be driving this exposure. In a recent study published [...]